Creso Pharma (ASX: CPH) has received approval from Brazilian health regulatory agency ANVISA to import their medicinal cannabis product cannaQIX® 50.
Sales and marketing of the product will be assisted by SIN Solution, who will also support patient access, while MedDepot will cover distribution. This follows a number of distribution deals for the cannaQIX® range including in New Zealand, Switzerland, UK.
Jorge Wernli, Commercial Director of Creso Pharma said, “We are excited to receive this ANVISA approval for our first medicinal cannabis product for the Brazilian market. We can now provide patients in Brazil with access to the cannaQIX® 50 product line which has additional benefits, particularly bioavailabilty, compared to currently available medical cannabis oils on the market. The challenge with medical cannabis products is the efficient delivery of the natural full spectrum plant substances to the body – a challenge that we at Creso have managed to overcome.”
Alessandra Cesar, Director of SIN Solution said, “Patients’ access to these new medical cannabis products with improved delivery systems will provide greater benefits and lead to a positive health-economic impact on the Brazilian healthcare system. We are excited to be working with Creso on this marketing initiative.”
CannaQIX 50® was developed to treat chronic pain, particularly related to neuropathic diseases such as multiple sclerosis, Parkinsons and cancer.